Long-term outcomes of drug-eluting stents versus bare-metal stents in saphenous vein graft disease: Results from the prairie "real world" stent registry

Catheterization and Cardiovascular Interventions

Volumn 75, Issue 1, 2010, Pages 93-100

  Goswami, Nilesh J ^a,b,c   Gaffigan, Matthew ^c   Berrio, Gadiel ^c   Plessa, Anna L ^b   Pfeiffer, Amanda M ^b   Markwell, Stephen J ^c   Mishkel, Gregory J ^a,b,c  

^a ST JOHN'S HOSPITAL   (United States)

^b Prairie Education and Research Cooperative   (United States)

^c SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bypass grafts coronary; Complications adult cath intervention; Percutaneous coronary intervention

Indexed keywords

ADULT; AGED; ARTICLE; BARE METAL STENT; CONTROLLED STUDY; CORONARY STENT; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; REVASCULARIZATION; RISK ASSESSMENT; SCORING SYSTEM; SURVIVAL RATE; TREATMENT OUTCOME; VEIN GRAFT DISEASE;

AGED; AGED, 80 AND OVER; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY ARTERY BYPASS; CORONARY RESTENOSIS; DRUG-ELUTING STENTS; FEMALE; GRAFT OCCLUSION, VASCULAR; HOSPITAL MORTALITY; HUMANS; KAPLAN-MEIERS ESTIMATE; LOGISTIC MODELS; MALE; METALS; MIDDLE AGED; MYOCARDIAL INFARCTION; PROPORTIONAL HAZARDS MODELS; PROSTHESIS DESIGN; RECURRENCE; REGISTRIES; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SAPHENOUS VEIN; STENTS; THROMBOSIS; TIME FACTORS; TREATMENT OUTCOME; VASCULAR PATENCY;

EID: 74249090627     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.22194     Document Type: Article

References (29)

1. Campeau L, Enjalbert M, Lesperance J, Vaislic C, Grondin CM, Bourassa MG. Atherosclerosis and late closure of aortocoronary saphenous vein grafts: Sequential angiographic studies at 2 weeks, 1 year, 5 to 7 years, and 10 to 12 years after surgery. Circulation 1983;68(Suppl II):II1-II7.
2. Fitzgibbon GM, Kafka HP, Leach AJ, Keon WJ, Hooper GD, Burton JR. Coronary bypass graft fate and patient outcome: Angiographic follow-up of 5,065 grafts related to survival and reoperation in 1,388 patients during 25 years. J Am Coll Cardiol 1996;28:616-626.
3. Goldman S, Zadina K, Moritz T, et al. Long-term patency of saphenous vein and left internal mammary artery grafts after coronary artery bypass surgery: Results from a Department of Veterans Affairs Cooperative Study. J Am Coll Cardiol 2004;44:2149-2156.
4. Foster ED. Reoperation for coronary artery disease. Circulation 1985;72:V59-V64.
5. Salomon NW, Page US, Bigelow JC, Krause AH, Okies JE, Metzdorff MT. Reoperative coronary surgery: Comparative analysis of 6591 patients undergoing primary bypass and 508 patients undergoing reoperative coronary artery bypass. J Thorac Cardiovasc Surg 1990;100:250-259.
6. de Jaegere PP, van Domburg RT, de Feyter PJ, et al. Long-term clinical outcome after stent implantation in saphenous vein grafts. J Am Coll Cardiol 1996;28:89-96.
7. Keeley EC, Velez CA, O'Neill WW, Safian RD. Long-term clinical outcome and predictors of MACE after percutaneous interventions on saphenous vein grafts. J Am Coll Cardiol 2001;38:659-665.
8. Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002;346:1773-1780.
9. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315-1323.
10. Stone GW, Ellis SG, Cox DA, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004;350:221-231.
11. Hoye A, Lemos PA, Arampatzi CA, et al. Effectiveness of the sirolimus-eluting stent in the treatment of saphenous vein graft disease. J Invas Cardiol 2004;16:230-233.
12. Price MJ, Sawhney N, Kao JA, Madrid A, Schatz RA, Teristein PS. Clinical outcomes after sirolimus-eluting stent implantation for de novo saphenous vein graft lesions. Catheter Cardiovasc Interv 2005;65:208-211.
13. Tsuchida K, Ong ATL, Aoki J, et al. Immediate and one-year outcome of percutaneous intervention of saphenous vein graft disease with paclitaxel-eluting stents. Am J Cardiol 2005;96:395-398.
14. Ge L, Iakovou I, Sangiorgi GM, et al. Treatment of saphenous vein graft lesions with drug-eluting stents: Immediate and midterm outcome. J Am Coll Cardiol 2005;45:989-994.
15. Vermeersch P, Agostoni P, Verheye S, et al. Randomized double-blind comparison of sirolimus-eluting stent versus bare-metal stent implantation in diseased saphenous vein grafts: Six-month angiographic, intravascular ultrasound, and clinical follow-up of the RRISC Trial. J Am Coll Cardiol 2006;48:2423-2431.
16. Hoffman R, Pohl T, Köster R, Blindt R, Boeckstegers P, Heitzer T. Implantation of paclitaxel-eluting stents in saphenous vein grafts: Clinical and angiographic follow-up results from a multicentre study. Heart 2007;93:331-334.
17. Wöhrle J, Nusser T, Kestler HA, Kochs M, Hombach V. Comparison of the slow-release polymer-based paclitaxel-eluting taxus-express stent with the bare-metal Express stent for saphenous vein graft interventions. Clin Res Cardiol 2007;96:70-76.
18. Brilakis ES, Lichtenwalter C, deLemos JA, et al. A randomized controlled trial of a paclitaxel-eluting stent versus a similar bare-metal stent in saphenous vein graft lesions. J Am Coll Cardiol 2009;53:919-928.
19. Jim MH, Ho HH, Ko RL, et al. Paclitaxel-eluting stent long-term outcomes in percutaneous saphenous vein graft interventions (PELOPS) study. J Am Cardiol 2009;103:199-202.
20. Chu WW, Rha SW, Kuchulakanti PK, et al. Efficacy of sirolimus-eluting stents compared with bare metal stents for saphenous vein graft intervention. Am J Cardiol 2006;97:34-37.
21. Vignali L, Saia F, Manari A, et al. Long-term outcomes with drug-eluting stents versus bare metal stents in the treatment of saphenous vein graft disease (results from the REgistro Reginale Angioplastiche Emilia-Romagna Registry). Am J Cardiol 2008;101:947-952.
22. Bansal D, Muppidi R, Singla S, et al. Percutaneous intervention on the saphenous vein bypass grafts - Long-term outcomes. Catheter Cardiovasc Interv 2008;71:58-61.
23. Ellis SG, Kandzari D, Kereiakes DJ, et al. Utility of sirolimus-eluting CypherTM stents to reduce 12-month target vessel revascularization in saphenous vein graft stenosis: Results of a multicenter 350-patient case-control study. J Invas Cardiol 2007;10:404-409.
24. Okabe T, Lindsay J, Buch AN, et al. Drug-eluting stents versus bare metal stents for narrowing in saphenous vein grafts. Am J Cardiol 2008;102:530-534.
25. Hoffmann R, Hamm C, Nienaber CA, et al. Implantation of sirolimus-eluting stents in saphenous vein grafts is associated with high clinical follow-up event rates compared with treatment of native vessels. Coron Artery Dis 2007;18:559-564.
26. Vermeersch P, Agostoni P, Verheye S, et al. Increased late mortality after sirolimus-eluting stents versus bare-metal stents in diseased saphenous vein grafts: Results from the randomized DELAYED RRISC trial. J Am Coll Cardiol 2007;50:261-267.
27. Pucelikova T, Mehran R, Kirtane AJ, et al. Short- and long-term outcomes after stent-assisted percutaneous treatment of saphenous vein grafts in the drug-eluting era. Am J Cardiol 2008;101:63-68.
28. Cutlip DE, Windecker S, Mehran R, et al. Clinical endpoints in coronary stent trials: A case for standardized definitions. Circulation 2007;115:2344-2351.
29. D'Agostino RB. Propensity scores in cardiovascular research. Circulation 2007;115:2340-2343.